PHILADELPHIA, Aug. 21 /PRNewswire-FirstCall/ -- GlaxoSmithKline today announced that, beginning in February 2009, the company will proactively report educational and charitable grants provided to US health-related organizations. The report will be updated on a quarterly basis and will include grants provided to various organizations including hospitals, teaching institutions, managed care organizations, professional associations, patient advocacy groups, and continuing medical education companies.
GSK provides grants for programs and organizations that foster increased understanding of scientific, clinical, and healthcare issues, and contribute to the enhancement of patient care.
"GSK sponsors a range of third-party independent educational programs to increase awareness and knowledge about health-related issues," said Chris Viehbacher, President, North American Pharmaceuticals, GlaxoSmithKline. "By publishing information about our grants, we transparently identify the support we offer for independent and quality education to improve the delivery of health care for patients."
GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, visit GlaxoSmithKline on the World Wide Web at http://us.gsk.com.
Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK's operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2007.
CONTACT: US Media: Nancy Pekarek, +1-919-483-2839, or Mary Anne Rhyne,
+1-919-483-2839, or Sarah Alspach, +1-215-751-7709, or US Analyst-Investor:
Frank Murdolo, +1-215-751-7002, or Tom Curry, 1-215-751-5419, all of
GlaxoSmithKline
Web site: http://www.gsk.com/
http://us.gsk.com/
Company News On-Call: http://www.prnewswire.com/comp/801350.html /
